Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis.
The de novo pathway of sphingolipid synthesis has been identified recently as a novel means of generating ceramide during apoptosis. Furthermore, it has been suggested that the activation of dihydroceramide synthase is responsible for increased ceramide production through this pathway. In this study, accumulation of ceramide mass in Molt-4 human leukemia cells by the chemotherapy agent etoposide was found to occur primarily due to activation of the de novo pathway. However, when the cells were labeled with a substrate for dihydroceramide synthase in the presence of etoposide, there was no corresponding increase in labeled ceramide. Further investigation using a labeled substrate for serine palmitoyltransferase, the rate-limiting enzyme in the pathway, resulted in an accumulation of label in ceramide upon etoposide treatment. This result suggests that the activation of serine palmitoyltransferase is the event responsible for increased ceramide generation during de novo synthesis initiated by etoposide. Importantly, the ceramide generated from de novo synthesis appears to have a distinct function from that induced by sphingomyelinase action in that it is not involved in caspase-induced poly (ADP-ribose)polymerase proteolysis but does play a role in disrupting membrane integrity in this model system. These results implicate serine palmitoyltransferase as the enzyme controlling de novo ceramide synthesis during apoptosis and begin to define a unique function of ceramide generated from this pathway.
Perry
D K
DK
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Carton
J
J
Shah
A K
AK
Meredith
F
F
Uhlinger
D J
DJ
Hannun
Y A
YA
D000217:Acyltransferases / Q000378:metabolism*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis; D001692:Biological Transport; D020169:Caspases / Q000378:metabolism; D002518:Ceramides / Q000096:biosynthesis*; D004789:Enzyme Activation; D005047:Etoposide / Q000494:pharmacology*; D006801:Humans; D007938:Leukemia; D008861:Microsomes / Q000201:enzymology; D008954:Models, Biological; D009183:Mycotoxins / Q000494:pharmacology; D010088:Oxidoreductases / Q000032:analysis; D010168:Palmitates / Q000378:metabolism; D011065:Poly(ADP-ribose) Polymerases / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D051102:Serine C-Palmitoyltransferase; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D014343:Trypan Blue / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000972:Antineoplastic Agents, Phytogenic; D002518:Ceramides; D009183:Mycotoxins; D010168:Palmitates; D011480:Protease Inhibitors; D005047:Etoposide; D010088:Oxidoreductases; C108138:dihydroceramide desaturase; D000217:Acyltransferases; C495089:SPTLC2 protein, human; D051102:Serine C-Palmitoyltransferase; D011065:Poly(ADP-ribose) Polymerases; D020169:Caspases; D014343:Trypan Blue; D013110:Sphingosine; C005682:safingol